Skip to main content
. 2021 May 21;13:325–339. doi: 10.2147/BCTT.S308554

Table 2.

Socio-Epidemiological and Clinical–Pathological Variables in Breast Cancer

Variable N (%) p-value a EGFR mRNA EGFR Protein IGF-1R mRNA IGF-1R Protein
RQ (Median ± IQR) p-value b RQ (Median ± IQR) p-value b RQ (Median ± IQR) p-value b RQ (Median ± IQR) p-valueb
Age (years) 18–40 26 (21.0) <0.001* 1.85 ± 1.06 0.286 1.71 ± 0.92 0.546 1.30 ± 0.49 0.042* 1.19 ± 0.48 0.056
41–60 68 (54.8) 1.86 ± 1.31 1.77 ± 0.93 1.43 ± 0.86 1.31 ± 0.86
>60 30 (24.2) 1.57 ± 1.27 1.46 ± 1.24 1.81 ± 1.70 1.50 ± 1.59
Parity Parous 110 (88.7) <0.001* 1.79 ± 1.29 0.453 1.65 ± 1.08 0.434 1.45 ± 0.94 0.125 1.33 ± 0.89 0.109
Nulliparous 14 (11.3) 1.98 ± 1.27 1.81 ± 0.78 1.23 ± 0.65 1.09 ± 0.60
Personal background Smoking 27 (21.8) <0.001* 1.59 ± 1.31 0.372 1.51 ± 0.74 0.439 1.47 ± 1.27 0.782 1.29 ± 1.31 0.698
Ethylism 2 (1.6) 1.42 ± 0.09 1.33 ± 0.08 1.92 ± 0.02 1.81 ± 0.02
Smoking+Ethylism 13 (10.5) 2.46 ± 1.62 2.12 ± 1.45 1.31 ± 1.76 1.22 ± 1.63
NDN 82 (66.1) 1.87 ± 1.16 1.77 ± 0.99 1.42 ± 0.86 1.32 ± 0.87
Family background Breast cancer 29 (23.4) 0.011* 2.00 ± 1.24 0.413 1.84 ± 0.83 0.537 1.31 ± 1.99 0.519 1.20 ± 1.80 0.478
Other cancers 39 (31.5) 1.86 ± 1.33 1.71 ± 1.07 1.60 ± 1.14 1.49 ± 1.24
NDN 56 (45.2) 1.68 ± 1.21 1.58 ± 1.12 1.43 ± 0.69 1.30 ± 0.63
BMI (kg/m2) ≤25 47 (37.9) <0.001* 1.96 ± 1.13 0.041* 1.78 ± 1.03 0.022* 1.42 ± 0.78 0.851 1.29 ± 0.82 0.789
> 25 68 (54.8) 1.82 ± 1.36 1.67 ± 1.09 1.46 ± 1.33 1.30 ± 1.30
IMC not rated 9 (7.3) 1.35 ± 0.44 1.28 ± 0.33 1.68 ± 1.56 1.47 ± 1.52
Angiolymphatic invasion Present 55 (44.4) <0.001* 2.51 ± 1.05 0.001* 2.14 ± 0.92 0.001* 1.42 ± 0.87 0.087 1.27 ± 0.90 0.072
Absent 67 (54.0) 1.55 ± 0.61 1.41 ± 0.52 1.49 ± 0.85 1.38 ± 0.81
Not rated 2 (1.6) 1.21 ± 0.17 1.18 ± 0.17 0.88 ± 0.03 0.82 ± 0.01
Compromised lymph nodes 0 55 (44.4) 0.009* 1.57 ± 1.24 0.003* 1.41 ± 0.93 0.001* 1.42 ± 1.36 0.570 1.26 ± 1.22 0.491
1–3 27 (21.8) 1.85 ± 0.98 1.74 ± 0.89 1.62 ± 1.38 1.52 ± 1.38
>3 42 (33.9) 2.37 ± 1.27 1.91 ± 1.01 1.40 ± 0.53 1.25 ± 0.35
Tumor size (cm) <2 14 (11.3) <0.001* 2.12 ± 1.53 0.067 1.78 ± 1.12 0.114 1.42 ± 1.88 0.123 1.28 ± 1.80 0.282
2–5 69 (55.6) 1.59 ± 1.24 1.51 ± 1.00 1.54 ± 1.10 1.40 ± 0.97
>5 41 (33.1) 2.47 ± 1.27 1.89 ± 0.97 1.33 ± 0.61 1.22 ± 0.56
Immunohistochemistry ER >10 105 (84.7) 0.002* 1.80 ± 1.28 0.718 1.61 ± 1.11 0.752 1.44 ± 1.37 0.584 1.29 ± 1.38 0.562
ER ≤10 19 (15.3) 1.96 ± 1.09 1.77 ± 0.84 1.42 ± 0.56 1.33 ± 0.56
Follow-up DFS 81 (65.3) <0.001* 1.58 ± 1.14 0.023* 1.50 ± 0.89 0.012* 1.60 ± 1.31 0.14 1.45 ± 1.25 0.292
Relapse or metastasis 16 (12.9) 1.93 ± 1.10 1.79 ± 0.68 1.44 ± 1.49 1.27 ± 1.59
Death 27 (21.8) 2.57 ± 1.27 2.11 ± 1.02 1.29 ± 0.30 1.19 ± 0.38
Access time to treatment
(months) 		1 27 (21.8) 0.015* 1.58 ± 1.23 0.502 1.45 ± 0.88 0.322 1.42 ± 0.79 0.396 1.33 ± 0.70 0.414
02–03 53 (42.7) 1.89 ± 1.34 1.74 ± 1.15 1.38 ± 0.98 1.24 ± 0.92
>03 44 (35.5) 1.83 ± 1.01 1.71 ± 0.92 1.47 ± 1.21 1.37 ± 1.32
Biological profile Luminal A 25 (20.2) <0.001* 1.54 ± 0.65 0.001* 1.39 ± 0.61 0.001* 1.99 ± 1.18 0.001* 1.81 ± 1.17 0.001*
Luminal B 33 (26.6) 1.58 ± 1.17 1.51 ± 1.03 2.78 ± 1.87 2.47 ± 1.74
Luminal B HER 8 (6.5) 1.38 ± 0.39 1.33 ± 0.30 1.01 ± 0.21 0.94 ± 0.24
Triple-negative 50 (40.3) 2.48 ± 1.11 1.93 ± 0.82 1.25 ± 0.43 1.14 ± 0.34
HER overexpression 8 (6.45) 2.74 ± 1.86 2.62 ± 1.75 1.28 ± 0.36 1.19 ± 0.30

Notes: aP-value of the χ2 test; bp-value of the Kruskal–Wallis test. *p-value <0.05, significantly different between groups. n: number of samples; RQ: relative quantification in which the combined non-neoplastic sample was designated as the calibrator for each neoplastic sample; T/N: the protein expression ratio between corresponding neoplastic and non-neoplastic samples.

Abbreviations: BMI, body mass index; ER, estrogen receptor; DFS, disease-free survival; NDN, nothing noteworthy; IQR: interquartile range.